Vyne Therapeutics (VYNE) showcases a strong fundamental investment potential with a robust cash flow of
42.9M and a high current ratio of 7.60X, indicating the company's strong liquidity position. Despite an EPS estimate of a loss of 3.15 for the current year, the company's book value per share stands at a strong 8.08X, reflecting substantial intrinsic value. Furthermore, Vyne's target price is set at a promising
63.33, significantly higher than its 52-week high of 8.73, hinting at a potentially high return on investment. However, investors should also consider the company's negative return on assets of 0.4 and a net income before tax showing a loss of 33.9M. Despite these challenges, the company's solid cash position and high book value per share demonstrate its potential for long-term growth.
Further analysis
The company, Vyne Therapeutics, has a beta of -0.2053, indicating relatively insignificant fluctuations compared to the market. As market returns increase, returns on Vyne Therapeutics are expected to decrease at a much slower rate. During a bear market, Vyne Therapeutics is likely to outperform the market.
While it's important to monitor Vyne Therapeutics' current price movements, caution should be exercised when using equity historical returns. Our approach to predicting any stock's future performance involves examining both its past performance charts and the business as a whole, including all available technical indicators.
Vyne Therapeutics provides twenty-seven different technical indicators that can assist in evaluating its performance. The expected return of Vyne Therapeutics is -0.2%. It's crucial to validate Vyne Therapeutics' value at risk, as well as the relationship between the skewness and day median price, to determine if Vyne Therapeutics' past performance will be replicated at some point in the near future.
Typically, a company's
financial statements are the reports that show the
financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Vyne Therapeutics income statement, its balance sheet, and the statement of cash flows. Potential Vyne Therapeutics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Vyne Therapeutics investors may use each financial statement separately, they are all related. The changes in Vyne Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Vyne Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our
technical analysis and
fundamental analysis pages.
The goal of Vyne Therapeutics
fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Vyne Therapeutics performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Vyne Therapeutics shares is the value that is considered the true value of the share. If
the intrinsic value of Vyne is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Vyne Therapeutics. Please read more on our
fundamental analysis page.
How effective is Vyne Therapeutics in utilizing its assets?
Vyne Therapeutics reports assets on its Balance Sheet. It represents the amount of Vyne resources that either has an existing economic value or will provide some form of benefits in the future. By effectively utilizing its assets, Vyne Therapeutics aims to generate revenue, control costs, drive operational efficiency, and enhance profitability. Optimizing asset utilization helps maximize shareholder value and maintain a competitive position in the Biotechnology space. To get a better handle on how balance sheet or income statements item affect Vyne volatility, please check the breakdown of all its
fundamentals.
Are Vyne Therapeutics Earnings Expected to grow?
The
future earnings power of Vyne Therapeutics involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Vyne Therapeutics factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Vyne Therapeutics
stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Vyne
expected earnings.
Vyne Therapeutics Gross Profit
Vyne Therapeutics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Vyne Therapeutics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Vyne Therapeutics Gross Profit growth over the last 10 years. Please check Vyne Therapeutics'
gross profit and other
fundamental indicators for more details.
Breaking it down a bit more
Vyne Therapeutics price dip over the last few months may raise some interest from shareholders as it is trading at a share price of
5.60 on
22,440 in trading volume. The company executives were not very successful in positioning the company resources to exploit
market volatility in
July. However, diversifying your holdings with Vyne Therapeutics or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 6.82. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Vyne Therapeutics partners.
| 2022 | 2023 (projected) |
PPandE Turnover | 37.33 | 38.32 | Long Term Debt to Equity | 0.8 | 0.79 |
Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Vyne Therapeutics has an asset utilization ratio of 1.17 percent. This indicates that the company is making $0.0117 for each dollar of assets. An increasing asset utilization means that Vyne Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.
| Current Assets | 59.51 Million | 94.89 |
| Assets Non Current | 3.2 Million | 5.11 |
Vyne Therapeutics (NASDAQ: VYNE) is a healthcare company that has shown potential for solid investment. The company's 52-week high stands at $8.73, while its 52-week low is at $1.9926, indicating a significant range for investors to consider. Vyne Therapeutics has a beta of 1.35, suggesting a higher volatility compared to the overall market. The company's total operating expenses stand at $34.8M, with a significant portion ($16.4M) attributed to selling, general, and administrative expenses. Vyne Therapeutics' total current liabilities amount to $9.3M, while the company has a working capital of $28.93M, suggesting a strong short-term
financial health. The company's earnings per share (EPS) estimate for the next quarter is a loss of $2.64, while the EPS estimate for the next year is a loss of $2.11. The company's return on assets is -0.4, indicating that the company is currently not profitable. The company's shares float is 3.1M, with 1.40% of shares owned by insiders and 11.08% by institutions. The company's short percent stands at 0.0203, with a short ratio of 5.22X. The Wall Street target price for Vyne Therapeutics is an impressive
$63.33, suggesting a significant potential upside. The company's cash per share stands at 0.74X, while it has a net debt of
-$31.3M, indicating a strong financial position.
Can Vyne Therapeutics build up on the latest surge?
Vyne Therapeutics has recently exhibited promising signs in the market, with the latest semi-deviation standing at 6.86. This suggests a higher likelihood of extreme upward price movement, which could potentially yield significant returns for investors. However, it's essential to bear in mind that semi-deviation also signifies the risk of extreme losses. Therefore, while the recent surge in
Vyne Therapeutics' stock price is promising, investors should carefully weigh the inherent volatility and potential risks before deciding to capitalize on this upward trend. Vyne Therapeutics is demonstrating above-average volatility over the chosen time horizon. Investors should thoroughly analyze Vyne Therapeutics independently to ensure that their intended
market timing strategies align with their expectations about the company's volatility. Understanding different
market volatility trends can often assist investors in timing the market. Proper use of volatility indicators allows traders to gauge the risk of Vyne Therapeutics' stock against market volatility during both bullish and bearish trends.
The heightened level of volatility that accompanies bear markets can directly affect Vyne Therapeutics' stock price, adding stress for investors as they watch the value of their shares plummet. This typically compels investors to rebalance their portfolios by purchasing different stocks as prices drop. In light of the recent 13 percent ascent of Vyne Therapeutics (VYNE), the stock presents a compelling investment opportunity. The analyst overall consensus is a 'Buy' with three strong buys and one hold. The estimated target price is valued at
$36.313, a significant upside from the current market value of
$5.6. The highest estimated target price even reaches
$71.941, suggesting a potential for substantial returns. However, investors should also consider the lowest estimated target price of $9 and the real value of $12.72. Despite the modest market dip, Vyne's performance and promising valuation metrics indicate a potentially lucrative investment opportunity. .
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Vyne Therapeutics. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
[email protected]